PET/MR Imaging of Somatostatin Receptor Expression and Tumor Vascularity in Meningioma: Implications for Pathophysiology and Tumor Outcomes.
DCE = dynamic contrast enhanced
DCE Perfusion MRI
DOTATATE
PET/MRI
meningioma
somatostatin receptor
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
11
2021
accepted:
21
12
2021
entrez:
14
2
2022
pubmed:
15
2
2022
medline:
15
2
2022
Statut:
epublish
Résumé
Meningiomas, the most common primary intracranial tumor, are vascular neoplasms that express somatostatin receptor-2 (SSTR2). The purpose of this investigation was to evaluate if a relationship exists between tumor vascularity and SSTR2 expression, which may play a role in meningioma prognostication and clinical management. Gallium-68-DOTATATE PET/MRI with dynamic contrast-enhanced (DCE) perfusion was prospectively performed. Clinical and demographic patient characteristics were recorded. Tumor volumes were segmented and superimposed onto parametric DCE maps including flux rate constant ( Thirty-six patients with 60 meningiomas (20 WHO-1, 27 WHO-2, and 13 WHO-3) were included. Mean DOTATATE PET/MRI demonstrated a strong significant correlation between tumor vascularity and SSTR2 expression in WHO-2 and WHO-3, but not WHO-1 meningiomas, suggesting biological differences in the relationship between tumor vascularity and SSTR2 expression in higher-grade meningiomas, the predictive value of which will be tested in future work.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Meningiomas, the most common primary intracranial tumor, are vascular neoplasms that express somatostatin receptor-2 (SSTR2). The purpose of this investigation was to evaluate if a relationship exists between tumor vascularity and SSTR2 expression, which may play a role in meningioma prognostication and clinical management.
MATERIALS AND METHODS
METHODS
Gallium-68-DOTATATE PET/MRI with dynamic contrast-enhanced (DCE) perfusion was prospectively performed. Clinical and demographic patient characteristics were recorded. Tumor volumes were segmented and superimposed onto parametric DCE maps including flux rate constant (
RESULTS
RESULTS
Thirty-six patients with 60 meningiomas (20 WHO-1, 27 WHO-2, and 13 WHO-3) were included. Mean
CONCLUSION
CONCLUSIONS
DOTATATE PET/MRI demonstrated a strong significant correlation between tumor vascularity and SSTR2 expression in WHO-2 and WHO-3, but not WHO-1 meningiomas, suggesting biological differences in the relationship between tumor vascularity and SSTR2 expression in higher-grade meningiomas, the predictive value of which will be tested in future work.
Identifiants
pubmed: 35155210
doi: 10.3389/fonc.2021.820287
pmc: PMC8832502
doi:
Types de publication
Journal Article
Langues
eng
Pagination
820287Informations de copyright
Copyright © 2022 Roytman, Kim, Glynn, Thomas, Lin, Feltus, Magge, Liechty, Schwartz, Ramakrishna, Karakatsanis, Pannullo, Osborne, Knisely and Ivanidze.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neuro Oncol. 2016 Jul;18(7):1021-7
pubmed: 26865086
J Neuroimaging. 2019 Sep;29(5):650-656
pubmed: 31107591
Neurosurg Focus. 2019 Jun 1;46(6):E10
pubmed: 31153141
BMC Cancer. 2021 Apr 1;21(1):348
pubmed: 33794813
Handb Clin Neurol. 2020;169:153-165
pubmed: 32553286
J Mol Histol. 2021 Apr;52(2):233-243
pubmed: 33528717
Neuro Oncol. 2016 Nov;18(11):1538-1547
pubmed: 27106404
Neurooncol Adv. 2021 Jan 21;3(1):vdab012
pubmed: 33738446
World J Surg Oncol. 2018 Dec 21;16(1):239
pubmed: 30577820
Curr Oncol Rep. 2020 Jul 3;22(8):84
pubmed: 32617743
AJNR Am J Neuroradiol. 2006 Feb;27(2):409-17
pubmed: 16484420
Expert Rev Anticancer Ther. 2020 Mar;20(3):197-203
pubmed: 32116057
AJR Am J Roentgenol. 2016 Mar;206(3):559-65
pubmed: 26901012
Clin Imaging. 2019 Jul - Aug;56:146-154
pubmed: 31121520
J Comput Assist Tomogr. 2012 Jan-Feb;36(1):125-30
pubmed: 22261782
AJNR Am J Neuroradiol. 2003 Sep;24(8):1554-9
pubmed: 13679270
Neuroimage Clin. 2014 Sep 10;6:262-74
pubmed: 25379439
J Neurosurg. 2015 Jan;122(1):4-23
pubmed: 25343186
AJR Am J Roentgenol. 2012 Jun;198(6):1277-88
pubmed: 22623539
Eur Radiol. 2004 Feb;14(2):309-17
pubmed: 14531000
J Nucl Med. 2016 May;57(5):708-14
pubmed: 26769865
Eur J Radiol. 2015 Apr;84(4):623-30
pubmed: 25641009
AJR Am J Roentgenol. 2011 Apr;196(4):886-90
pubmed: 21427341
J Comput Assist Tomogr. 1991 Jul-Aug;15(4):621-8
pubmed: 2061479
Clin Imaging. 2020 Oct;66:18-22
pubmed: 32442855
Clin Nucl Med. 2015 Mar;40(3):237-40
pubmed: 25608146
J Magn Reson Imaging. 2019 Sep;50(3):798-809
pubmed: 30663160
Clin Neurol Neurosurg. 2016 Feb;141:117-21
pubmed: 26780494
PLoS One. 2016 Nov 1;11(11):e0163554
pubmed: 27802268
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Magn Reson Med. 1990 Oct;16(1):117-31
pubmed: 2255233
Neuroradiology. 2008 Oct;50(10):835-40
pubmed: 18542938
Magn Reson Med. 2011 Sep;66(3):735-45
pubmed: 21384424
J Magn Reson Imaging. 2020 Nov;52(5):1360-1373
pubmed: 32524658
Neuroradiology. 2020 Nov;62(11):1441-1449
pubmed: 32583368
Neurosurg Clin N Am. 2016 Apr;27(2):137-43
pubmed: 27012378
Radiographics. 2015 Mar-Apr;35(2):500-16
pubmed: 25763733
Br J Radiol. 2021 Oct 1;94(1126):20210403
pubmed: 34357794
J Magn Reson Imaging. 1999 Sep;10(3):223-32
pubmed: 10508281